Uroplasty, Inc., a medical device company, engages in the development, manufacture, and marketing of products for the treatment of voiding dysfunctions. The company offers Urgent PC system, a minimally invasive and office-based neurostimulation therapy for the treatment of urinary symptoms, such as urinary urgency, urinary frequency, and urge incontinence associated with overactive bladder; and Macroplastique, a minimally invasive, implantable soft tissue urethral bulking agent for the treatment of adult female stress urinary incontinence. It also provides PTQ Implants, which offer minimally-invasive and soft-textured permanent implant for treatment of fecal incontinence; and VOX Implants, a tissue bulking material for otolaryngology vocal cord rehabilitation applications, as well as distributes wound care products. The company offers its products primarily to urologists, urogynecologists, and gynecologists through direct field sales personnel and independent sales representatives in the United States, as well as through direct sales organization in the United Kingdom and the Netherlands, and through distributors in other markets. Uroplasty, Inc. was incorporated in 1992 and is headquartered in Minnetonka, Minnesota.
|
